Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1842 - Long-Term Effects of Sonidegib on Tumor Burden: 30-Month Results from the Phase 2 Randomized BOLT Trial

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Skin Cancers

Presenters

Reinhard Dummer

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

R. Dummer1, M. Migden2

Author affiliations

  • 1 Dermatology, University of Zurich Hospital, 8091 - Zurich/CH
  • 2 Medical Affairs, MD Anderson Cancer Center, Houston/US
More

Resources

Abstract 1842

Background

Sonidegib, a hedgehog pathway inhibitor (HPI), is approved in the United States and European Union for locally advanced basal cell carcinoma (laBCC) based on primary results from the BOLT trial (Migden, Lancet, 2015). Updated data from 30-months analysis demonstrated continued efficacy and manageable safety (Dummer ASCO 2016). Here we present 30-month tumor burden results, which have not previously been presented or published.

Methods

Eligible HPI-treatment-naïve patients with laBCC not amenable to curative surgery/radiotherapy or patients with metastatic BCC (mBCC) were randomized 1:2 to receive sonedegib 200 or 800 mg QD. For all patients, tumor burden was assessed as decrease of best percentage change from baseline by central review. For patients with laBCC, tumor lesions were assessed by photography and modified RECIST criteria; for patients with mBCC, photography or MRI/computed tomography (CT) and RECIST 1.1 were used.

Results

Evaluable patients at 30 months were from the primary efficacy analysis set (pEAS) for laBCC patients (200 mg, n = 32; 800 mg, n = 74) and mBCC patients (200 mg, n = 12; 800 mg, n = 19). Consistent with the primary, 12- and 18-month analyses, 96.9% (n = 31) and 94.6% (n = 70) of patients with laBCC experienced a substantial reduction in tumor size with sonidegib 200 and 800 mg, respectively. Reduction in target lesions for patients with mBCC receiving 200 mg was 91.7% (n = 11) across all time points; for the 800 mg group, 84.2% (n = 16) of patients experienced reduction in tumor lesions in the primary, 12-, 18-month analyses and 89.5% (n = 17) at 30 months. Sonidegib 200 mg had a more favorable safety profile compared to 800 mg, with lower rates of grade 3/4 adverse events (AEs; 43.0% vs 64.0%) and AESs events leading to discontinuation (30.4% vs 40.0%).

Conclusions

Sonedegib 200 and 800 mg in patients with laBCC and mBCC demonstrated substantial target tumor lesion reduction across 30 months. Safety/tolerability was manageable and similar across 30 months with no new side effects emerging following the primary analysis.

Clinical trial identification

NCT01327053

Legal entity responsible for the study

Novartis Pharmaceuticals

Funding

Sun Pharmaceutical Industries Ltd.

Disclosure

R. Dummer: Received research funding from Novartis, Merck, Bristol-Myers Squibb, Roche, and GlaxoSmithKline and has served as a consultant/advisory board for Novartis, Merck, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Amgen, and Takeda. M. Migden: Participated on advisory boards and received honoraria from Genentech, Inc.; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; and Sun Pharmaceuticals

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.